Search

This retrospective study of 638 renal transplant patients shows that a high estimated tacrolimus clearance (daily tacrolimus dose [mg]/trough concentration [µg/L]) >1.5 associates with biopsy-proven acute rejection in the first 90 days posttransplantation. Supplemental digital content is available in the text.

Pharmacokinetic analysis of generic and original brand tacrolimus preparations in elderly recipients shows that the 2 formulations were not bioequivalent, resulting in greater drug exposure with the generic formulation.

Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy with fluvastatin, pravastatin, or atorvastatin. These agents may not sufficiently lower lipid levels, and therefore, a more potent agent like rosuvastatin maybe needed.

Obesity is a common problem following renal transplantation. Rimonabant, a cannabinoid-1 receptor blocker, offers a new approach for reducing obesity.

Supplemental digital content is available in the text.